Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

Fig. 5

Treatment with CAELYX®, LTX-315, and the combination of both reshapes the tumor microenvironment. Tumors (n = 8) were harvested on day 14 (day 7 post treatment) and stained for an array of immune cell markers before being analyzed by flow cytometry. Images show flow cytometry determination of live cells (a), CD45+ leukocytes (b), CD3+ T lymphocytes (c), CD4+ T cells (d). and CD8+ cytotoxic T cells (e). Each dot represents data for one mouse. Student’s t test: *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us